Sim&Cure Secures 10 M€ Series extension to Revolutionize Neurovascular Procedures

Round led by Elaia, with participation from IT Translation Investissement, IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Tudigo and Holnest.

Montpellier, France — 28/11/2025 — Sim&Cure, a pioneer in AI-driven Digital Twin software for neurovascular treatments, has closed a 10 million euro Series extension round. The proceeds will support the company’s international expansion, particularly in China and the Asia-Pacific region, accelerate the development of its software portfolio, and strengthen its R&D and commercial teams.

Addressing a significant healthcare challenge

Cerebral aneurysms affect an estimated 3–5 % of the population. Each year, nearly 500,000 people worldwide experience a rupture, with a high rate of mortality and long-term disability among survivors. Despite major progress in imaging and interventional techniques, aneurysms remain frequently underdiagnosed and are often detected after rupture, which complicates treatment and increases healthcare costs.

Sim&Cure develops software solutions designed to assist healthcare professionals in planning endovascular procedures more safely and efficiently through patient-specific simulation. By leveraging Digital Twin and AI technologies, the company aims to support better-informed clinical decision-making while contributing to improved procedure planning.

Technology supporting precision in treatment planning

The company’s flagship product, Sim&Size™, provides physicians with a patient-specific digital representation that allows them to simulate multiple endovascular treatment scenarios prior to intervention. This approach is intended to help clinicians anticipate technical challenges and evaluate device positioning options.

Since its creation in 2014, Sim&Cure has focused on bringing advanced simulation capabilities into daily clinical workflows. Sim&Size™ is used in 45+ countries and has been deployed in collaboration with over 700 healthcare professionals, contributing to more than 35000 of treatment planning procedures.

Strategic collaborations with industry leaders such as Siemens Healthineers and Philips aim to integrate Sim&Cure’s technology into advanced imaging ecosystems, bringing simulation tools closer to physicians’ existing environments.

Sim&Cure has also diversified its product portfolio with the launch of Sim&Train a training platform using 3D printing technology and, more recently, Sim&Predict, an AI software to detect automatically cerebral aneurysm in medical images.

Sustained investor confidence to scale global growth

The Series extension supported from historical investors Elaia and IT Translation Investissement, alongside IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Tudigo and Holnest. Their renewed commitment underscores long-term confidence in Sim&Cure’s vision and its potential to shape the future of personalized endovascular care.

Mathieu Sanchez, CEO and co-founder of Sim&Cure, commented:
 “This funding is a testament to our team’s dedication and to the continued trust of our investors, especially Elaia and IT Translation Investissement, who have believed in our journey from the very beginning. With their support, and that of our new partners IRDI, SWEN, SOFILARO and HOLNEST, we are well positioned to accelerate our global development and pursue our mission to disrupt the management of cerebral aneurysm by promoting ta preventive and personalized approach.”

Investor Profiles

Elaia
 Elaia is a leading European venture capital firm backing bold technology entrepreneurs from seed to growth stage. With over €800 million under management, Elaia has a strong track record of supporting deep tech and digital health startups with global ambitions.

IT Translation Investissement
 IT Translation Investissement is a specialized early-stage investor dedicated to transforming high-potential research projects in digital and deep tech into successful companies. By combining financing and operational expertise, the firm helps bridge the gap between academic innovation and commercial success.

IRDI Capital Investissement
 Based in Toulouse, Montpellier, and Bordeaux, IRDI Capital Investissement has been investing for over 40 years in companies at all stages of development, from venture capital to growth and buyout capital. Managing more than €550 million, IRDI supports innovative companies in the Occitanie and Nouvelle-Aquitaine regions of France.

SWEN Capital Partners
 SWEN Capital Partners is a leading European asset management firm specializing in sustainable investments across private equity, infrastructure, and private debt. With more than €9.5 billion under management, SWEN integrates ESG criteria across all its investments and has been a pioneer in climate strategies since 2017.

Sofilaro
 Sofilaro, a regional private equity firm and subsidiary of Crédit Agricole du Languedoc, supports SMEs and startups based in the South of France for 40 years, and sustains projects that create value and long-term economic impact in the Occitanie region. Its recent dedicated VC fund, SOFILARO Innovation, is managing more than €35 million, and invests in innovative and tech startups, from seed to growth stages.

Tudigo
 Tudigo is a French investment platform that enables individuals and institutions to support high-potential startups. By connecting communities and investors, Tudigo fosters innovation, entrepreneurship, and sustainable regional development.

Holnest
 Holnest is the family office of Jean-Michel Aulas, founder of Cegid and former president of Olympique Lyonnais. The firm invests in promising entrepreneurial ventures, with a focus on innovation, technology, and long-term value creation.

About Sim&Cure

Sim&Cure is a medtech company transforming the management of cerebral aneurysms through a comprehensive and patient-centered approach. Founded in 2014 in Montpellier, France, the company combines Digital Twin technology and artificial intelligence to support clinicians across the entire care pathway.

Its solutions are designed to assist healthcare professionals in planning and assessing endovascular procedures, helping them achieve greater confidence and consistency in neurovascular treatment. With a growing global presence—including a U.S. subsidiary in New York and ongoing expansion across Asia—Sim&Cure collaborates with leading scientific, clinical, and industry partners such as Medtronic, Stryker, Terumo Neuro, Phenox, Siemens Healthineers and Philips to advance precision in patient care..

Media contact

Sim&Cure
 Mathieu Sanchez, CEO & Co-founder
 m.sanchez@sim-and-cure.com